Perspective Therapeutics Return on Equity

Perspective Therapeutics (ISR) currently reports a ROE of -35.95%. That is below the Industrials sector average of 20.41%. Use the charts on this page to explore Perspective Therapeutics's ROE history and peer comparisons.

Perspective Therapeutics's ROE of -35.95% is lower than the Industrials sector average of 20.41%. That is roughly 276.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Perspective Therapeutics's current -35.95% should be judged against Industrials norms (sector average: 20.41%) and against ISR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -35.95%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 20.41%. From there, open related valuation or income-statement pages for Perspective Therapeutics, and consider following ISR for alerts when major investors trade the stock.

Perspective Therapeutics is classified in the Industrials sector. On ROE, it currently shows -35.95% versus a sector average near 20.41%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing ISR with unrelated industries.